IDEXX Laboratories (NASDAQ:IDXX) Shares Gap Up - Here's Why

Key Points

• IDEXX Laboratories shares surged: The stock opened at $625 after previously closing at $551.21 and last traded near $643.21.
• Analyst sentiment remains positive overall: Eight analysts rate IDXX a Buy and six rate it a Hold, producing a “Moderate Buy” consensus and an average price target of $721.67, despite recent target reductions from JPMorgan and Jefferies.
• Recent results exceeded expectations: IDEXX reported quarterly EPS of $4.27 versus the $3.94 consensus and revenue of $1.22 billion, up 9.7% year over year; analysts expect full-year EPS of about $14.81.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report)'s stock price gapped up before the market opened on Monday. The stock had previously closed at $551.21, but opened at $625.00. IDEXX Laboratories shares last traded at $643.2080, with a volume of 380,773 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. KeyCorp initiated coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They issued a "sector weight" rating for the company. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating for the company in a research note on Friday, October 16th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday. They issued a "buy" rating for the company. Finally, Jefferies Financial Group cut their price objective on IDEXX Laboratories from $795.00 to $705.00 and set a "buy" rating on the stock in a research report on Tuesday, October 20th. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $721.67.

IDEXX Laboratories Stock Performance

The stock has a market cap of $50.41 billion, a P/E ratio of 44.79 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The business's 50-day moving average price is $534.27 and its 200-day moving average price is $574.09.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter last year, the business posted $3.50 earnings per share. The firm's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares of the company's stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.79% of the company's stock.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IDXX. Arlington Trust Co LLC lifted its holdings in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock worth $32,000 after acquiring an additional 19 shares during the last quarter. Bell Investment Advisors Inc grew its stake in IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company's stock worth $33,000 after purchasing an additional 20 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC boosted its stake in shares of IDEXX Laboratories by 21.4% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company's stock valued at $67,000 after buying an additional 21 shares during the period. Arlington Capital Management Inc. increased its position in shares of IDEXX Laboratories by 4.8% in the 1st quarter. Arlington Capital Management Inc. now owns 479 shares of the company's stock valued at $269,000 after purchasing an additional 22 shares during the last quarter. Finally, Valeo Financial Advisors LLC increased its holdings in IDEXX Laboratories by 6.4% in the second quarter. Valeo Financial Advisors LLC now owns 383 shares of the company's stock valued at $202,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.